A controversial vaccine trial that risked withholding lifesaving protection from newborns has been paused, but the danger isn't over. In Guinea-Bissau, Danish researchers proposed withholding the hepatitis B vaccine from half of newborns, despite the disease being widespread and potentially deadly. Now, global health leaders are making something clear: the focus must shift immediately from risky experiments to protecting every baby.
Sign the petition to demand that global health authorities prioritize universal hepatitis B vaccination at birth instead of pursuing harmful or unethical research.
The backlash was swift. Experts, lawmakers, and the World Health Organization raised serious ethical concerns, and the trial has now been paused. But pausing is not enough.
According to senior officials at Africa CDC, the real priority is clear: ensure every newborn receives the hepatitis B vaccine at birth as quickly as possible. This is not theoretical. This is proven, lifesaving care.
Hepatitis B can lead to chronic illness, liver failure, and death. The vaccine is safe, effective, and already widely recommended. Every delay in rollout puts more children at risk.
With one of the researchers behind this controversial trial closely tied to Robert F Kennedy Jr, secretary of the U.S. Department of Health and Human Services, there is a real risk that these same dangerous ideas could shape future vaccine policy far beyond Guinea-Bissau — putting even more lives at stake if left unchecked.
Sign the petition now to demand a comprehensive, ethical response that protects children, expands vaccine access, and puts public health above experimentation!
